294 related articles for article (PubMed ID: 19549328)
1. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours.
Albergaria A; Paredes J; Sousa B; Milanezi F; Carneiro V; Bastos J; Costa S; Vieira D; Lopes N; Lam EW; Lunet N; Schmitt F
Breast Cancer Res; 2009; 11(3):R40. PubMed ID: 19549328
[TBL] [Abstract][Full Text] [Related]
2. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
[TBL] [Abstract][Full Text] [Related]
3. Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores.
Ademuyiwa FO; Thorat MA; Jain RK; Nakshatri H; Badve S
Mod Pathol; 2010 Feb; 23(2):270-5. PubMed ID: 19946260
[TBL] [Abstract][Full Text] [Related]
4. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.
Thorat MA; Marchio C; Morimiya A; Savage K; Nakshatri H; Reis-Filho JS; Badve S
J Clin Pathol; 2008 Mar; 61(3):327-32. PubMed ID: 18037662
[TBL] [Abstract][Full Text] [Related]
5. Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.
Habashy HO; Powe DG; Rakha EA; Ball G; Paish C; Gee J; Nicholson RI; Ellis IO
Eur J Cancer; 2008 Jul; 44(11):1541-51. PubMed ID: 18538561
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet.
McCune K; Bhat-Nakshatri P; Thorat MA; Nephew KP; Badve S; Nakshatri H
Cancer Res; 2010 Jan; 70(2):685-96. PubMed ID: 20068169
[TBL] [Abstract][Full Text] [Related]
7. Loss of ERα and FOXA1 expression in a progression model of luminal type breast cancer: insights from PyMT transgenic mouse model.
McCune K; Mehta R; Thorat MA; Badve S; Nakshatri H
Oncol Rep; 2010 Nov; 24(5):1233-9. PubMed ID: 20878115
[TBL] [Abstract][Full Text] [Related]
8. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
11. Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients.
Ijichi N; Shigekawa T; Ikeda K; Horie-Inoue K; Shimizu C; Saji S; Aogi K; Tsuda H; Osaki A; Saeki T; Inoue S
Horm Cancer; 2012 Aug; 3(4):147-59. PubMed ID: 22476979
[TBL] [Abstract][Full Text] [Related]
12. Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Aishima S; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 Apr; 19(4):1145-52. PubMed ID: 21984487
[TBL] [Abstract][Full Text] [Related]
13. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value.
Voduc D; Cheang M; Nielsen T
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):365-73. PubMed ID: 18268121
[TBL] [Abstract][Full Text] [Related]
14. FOXA1 is an independent prognostic marker for ER-positive breast cancer.
Mehta RJ; Jain RK; Leung S; Choo J; Nielsen T; Huntsman D; Nakshatri H; Badve S
Breast Cancer Res Treat; 2012 Feb; 131(3):881-90. PubMed ID: 21503684
[TBL] [Abstract][Full Text] [Related]
15. High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancer.
Horimoto Y; Sasahara N; Sasaki R; Hlaing MT; Sakaguchi A; Saeki H; Arakawa A; Himuro T; Saito M
Breast Cancer Res Treat; 2020 Aug; 183(1):41-48. PubMed ID: 32572714
[TBL] [Abstract][Full Text] [Related]
16. The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014).
De Lara S; Nyqvist J; Werner Rönnerman E; Helou K; Kenne Sarenmalm E; Einbeigi Z; Karlsson P; Parris TZ; Kovács A
BMC Cancer; 2019 Feb; 19(1):187. PubMed ID: 30819139
[TBL] [Abstract][Full Text] [Related]
17. GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas.
Davis DG; Siddiqui MT; Oprea-Ilies G; Stevens K; Osunkoya AO; Cohen C; Li XB
Hum Pathol; 2016 Jan; 47(1):26-31. PubMed ID: 26527523
[TBL] [Abstract][Full Text] [Related]
18. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.
Jacquemier J; Charafe-Jauffret E; Monville F; Esterni B; Extra JM; Houvenaeghel G; Xerri L; Bertucci F; Birnbaum D
Breast Cancer Res; 2009; 11(2):R23. PubMed ID: 19405945
[TBL] [Abstract][Full Text] [Related]
19. FOXA1 represses the molecular phenotype of basal breast cancer cells.
Bernardo GM; Bebek G; Ginther CL; Sizemore ST; Lozada KL; Miedler JD; Anderson LA; Godwin AK; Abdul-Karim FW; Slamon DJ; Keri RA
Oncogene; 2013 Jan; 32(5):554-63. PubMed ID: 22391567
[TBL] [Abstract][Full Text] [Related]
20. Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases.
Horimoto Y; Arakawa A; Harada-Shoji N; Sonoue H; Yoshida Y; Himuro T; Igari F; Tokuda E; Mamat O; Tanabe M; Hino O; Saito M
Br J Cancer; 2015 Jan; 112(2):345-51. PubMed ID: 25422910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]